

A
Target: Mouse NGF
Optical Density
Mock
caN-HCA + caN-kLC-1
caN-HCB + caN-kLC-1
caN-HCC + caN-kLC-1
caN-HCD + caN-kLC-1
B
3H-thymidine incorporation (CPM)
20000
15000
10000
5000
0
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
Antagonist Dilution
caN-HCA1 + caN-KLC1
caN-HCB2 + caN-KLC1
caN-HCC1 + caN-KLC1
caN-HCD2 + caN-KLC1

Figure 1



Relative Complement C1q binding
A450- background
0.2
caN-HCA
caN-HCB
caN-HCC
caN-HCD

Figure 2




Figure 3a




Figure 3b



A
B
C
Complement Clq binding (A450- background)
0.3
0.2
0.1
0.3
0.2
0.1
1.0
caN-HCB
caN-HCC
huN-GI
huN-G4
caV-HCA
caV-HCB
muB-2a
muB-HCB

Figure 4




Figure 5.




Figure 6A




Figure 6B

SDS-PAGE





Figure 6C



Peak Retention time (Mins)	Approximate MW (KDa)	% of Total Peak area
8.05	353	2.6
9.17	156	89.7
11.18	36	7.7

Figure 6D



SDS-PAGE
Non-Reducing
Mouse MAb
NV-01
I II
230
150
100
80
60
50
40
30
25
Reducing
Mouse MAb
NV-01
I II
230
150
100
80
60
50
40
30
25

Figure 7A



NGF ELISA
O.D. 450 - background
1.2
1
0.8
0.6
0.4
0.2
0
II
I
0
20
40
60
80
100
NV-01 concentration (ng/ml)

Figure 7B

Study Day			-1	1	3	7
Animal ID	Sex	Age on Study Day 0 (months)				
68305	M	11	9.6	10.0	9.9	10.0
26885	F	19	9.2	9.9	9.5	9.8
32886	F	11	9.4	9.9	9.7	10.0

Study Day	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Animal ID															
68305	38.2	38.6	38.6	38.5	38.4	38.5	38.4	38.3	38.7	38.2	38.3	38.9	38.4	38.6	38.5
26886	37.8	38.2	38.0	38.2	38.4	37.7	38.1	38.2	38.4	38.2	38.4	38.6	38.5	38.4	38.6
32886	36.8	38.7	38.9	38.8	38.7	38.8	38.7	38.5	38.8	38.7	38.3	39.2	38.7	38.7	38.8

Figure 8



Serum NV-01 concentration (ug/mL)
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0
50
100
150
200
250
300
350
400
Hours Post Infusion
5 ug/ml at 14 d

Figure 9



3
2
1
0
Lameness Score
-1 0 1 2 3 4 5 6 7
Day
**
** p = 0.02
Vehicle
Anti-NGF MAb

Figure 10